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Background: Inflammatory bowel diseases (IBD) are chronic intestinal inflammatory diseases affecting about 1% of
western populations. New eating behaviors might contribute to the global emergence of IBD. Although the
immunoregulatory effects of omega-3 fatty acids have been well characterized in vitro, their role in IBD is controversial.
Methods: The aim of this study was to assess the impact of increased fish oil intake on colonic gene expression,
eicosanoid metabolism and development of colitis in a mouse model of IBD. Rag-2 deficient mice were fed fish oil (FO)
enriched in omega-3 fatty acids i.e. EPA and DHA or control diet for 4 weeks before colitis induction by adoptive
transfer of naïve T cells and maintained in the same diet for 4 additional weeks. Onset of colitis was monitored by
colonoscopy and further confirmed by immunological examinations. Whole genome expression profiling was made
and eicosanoids were measured by HPLC-MS/MS in colonic samples.
Results: A significant reduction of colonic proinflammatory eicosanoids in FO fed mice compared to control was
observed. However, neither alteration of colonic gene expression signature nor reduction in IBD scores was observed
under FO diet.
Conclusion: Thus, increased intake of dietary FO did not prevent experimental colitis.
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Inflammatory bowel diseases (IBD) is a term used to
cover a wide range of immune mediated diseases with-
out a well defined etiology that result in chronic relaps-
ing inflammation of the gut. The two major forms of
IBD are Crohn’s disease (CD) and ulcerative colitis (UC).
Genetic as well as environmental factors such as diet or
composition and activity of intestinal microbiota have
been implicated in IBD pathogenesis [1]. Experimental
colitis induced by adoptive transfer (AT) of syngenic
naïve T cells into lymphopenic mice is a well established* Correspondence: jalil.benyacoub@rdls.nestle.com
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reproduction in any medium, provided the oranimal model for IBD sharing a number of clinical, gen-
etic and immunological features with human IBD [2].
Research on the effect of dietary lipids on the immune
system has met great interest in the last decade. Amounts,
types of fat and active lipid metabolites such as eicosanoids
have an impact on immune cell function [3]. Long chain
(LC) n-6 polyunsaturated fatty acids (PUFA) found in
vegetable oils might promote proinflammatory responses
potentially detrimental for the host. In contrast, LC n-3
PUFA found in fish oil (FO), specifically eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), have been
reported to support anti-inflammatory responses and thus
have gained interest in the food industry. It is believed that
the potential anti-inflammatory properties of LC n-3 PUFA
may translate into important health benefits [4]. Indeed,
epidemiological studies have revealed that the westerntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition of the control and experimental
diets (in gram per kilogram of dry matter)
Nutrients (g/kg) Control diet (Experimental) FO-diet




Mineral mix AIN-93 M 35 35
Vitamin mix AIN-93 M 10 10
L-cysteine 3 3
Choline bitartrate 2.5 2.5
Butylhydroxytoluene 0.014 0.014
Total oil mixture 50 50
Corn oil (%) 35 0
Cocoa butter (%) 15 7
Soybean oil (%) 50 50
Sunflower oil (%) 0 23
Fish oil (%) 0 20
Table 2 Fatty acid composition of the control and
experimental diets











C20:5n-3 EPA 0.00 3.37
C22:0 0.29 0.28
C22:5n-3 0.00 0.37
C22:6n-3 DHA 0.00 2.10
Other 0.24 3.81
Results of duplicate analysis are expressed as% of total fatty acids per gram of
diet (dry matter).
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are more prone to develop chronic inflammatory diseases
[5]. Nowadays, many dietary interventions target reduc-
tion of n-6:n-3 PUFA dietary ratio by introduction of
marine products in the diet or n-3 PUFA supplements.
However, pre-clinical studies provide inconsistent results
on the anti-inflammatory properties of n-3 PUFA [6-20].
Indeed, in some studies n-3 PUFA display strong or mild
effects on animal model of IBD [6-9,12,13,15-18,20] and
in some other recent reports it was shown that a large
dietary intake of n-3 PUFA could even exacerbate colitis
[10,11,14,19]. The same discrepancies exist in clinics while
recent systematic reviews and meta-analyses conclude that
the available data are insufficient to draw any conclusions
on the benefit of increased LC n-3 PUFA consumption
for induction and/or maintenance of remission in IBD
patients [21-24]. In contrast, clinical trials in ICU patients
or in patients with rheumatoid arthritis have consistently
demonstrated the anti-inflammatory efficacy of LC n-3
PUFA intake as recently reviewed in [25].
The use of “omics” technologies for systems biology
with relevant animal models allow us to better understand
the basic molecular mechanisms of how foods or food
components like LC n-3 PUFA could prevent or amelior-
ate a disease such as IBD. Herein, using “omics” tech-
nologies and the well characterized mouse adoptive
transfer (AT) colitis model [2,26], we have evaluated the
properties of a LC n-3 PUFA-enriched diet under healthy
or inflammatory conditions and determined whether LC
n-3 PUFA-enriched diet may have a positive impact on
colitis prevention. Colonic mucosa gene expression and
eicosanoid metabolism were analyzed by transcriptomics
and eicosanomics. Altogether our results based on a colitis
mouse model allowed us to challenge the concept of effi-
cacy of increased dietary intake of LC n-3 PUFA with FO
for the prevention and management of IBD.
Results
Diet design and safety evaluation
In many studies, dietary oils are manipulated in order to
modify ratios of n-6:n-3 PUFA. Often, high proportion
of FO introduction leads to an increase in LC n-3 PUFA
by increasing EPA and DHA intake while LC n-6 PUFA
intake is reduced. Thus, the anti-inflammatory effects of
FO may result from reduced cell content in LC n-6
PUFA like linoleic acid (LA) or arachidonic acid (AA)
rather than the effect of EPA and DHA per se. Herein,
in order to avoid this as a confounding factor, our diet
described in Table 1 was designed to maintain LC n-6
PUFA and balanced for essential FA content in the
control and experimental diets as analyzed and shown
in Table 2. When wild type (WT) mice received this
diet for 8 weeks no safety issue was noticed, all animals
ate and grew normally. Immune cell subsets analysis(proportion and phenotype) by flow-cytometry in primary
(thymus and bone marrow) and secondary lymphoid tis-
sues (spleen) did not show any perturbation of myeloid
cells, B and T lymphocyte development and function (data
not shown). Therefore we decided next to test this diet in
a colitis protocol established earlier for colitis prevention
[2,26,27]. It was given to Rag2−/− immune-deficient mice
over a 4 week period before inducing IBD by AT of naïve
T cells. AT mouse model of colitis was chosen because it
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ber of clinical, genetic and immunological features with
the human disease [2,26]. The animals were kept under
the same diet and followed for an extra 4 week period (see
study design in Figure 1).
Colitis outcomes
Following AT, colitis usually develops within 3–7 weeks
and gets worse over time. To minimize animal suffering
and strictly focus on IBD prevention by dietary interven-
tion, we decided to stop at 4 weeks and focus on early
signs of intestinal inflammation. At the time of sacrifice,
as observed in Figure 2A, there was no significant weight
loss when comparing the transferred (t) and the non-
transferred (nt) animals. However, AT mice display a
22% reduction in fat mass (ntRag2 vs tRag2 P = 0.029,
Figure 2A, inset) as previously observed as an early hall-
mark of IBD onset [28]. Fat mass loss was even more
pronounced in FO fed AT animals reaching ~45% fat
mass reduction (Figure 2A, inset ntRag2 + FO and tRag2,
P = 0.001). Relative increased fat mass loss in tRag2 + FO
compared to tRag2 was close to being significant
(P = 0.089). The development of colitis upon AT was
confirmed with macroscopic parameters such as endo-
scopic evaluation (Figure 2B, median scores of 7 and 6,
tRag2 and tRag2 + FO, respectively) and an increased
colon weight to length (W/L) ratio of 40-70% (Figure 2C),
which was associated with a 4–13 fold increase in median
spleen weight and cellularity (data not shown). However
none of the macroscopic parameters of colitis showed
significant differences between control-fed and FO-fed
animals (Figure 2B-C).
In addition to the macroscopic parameters, immune
colitis hallmarks i.e. mucosal Th1/Th17 inflammatory
disease with immune cell infiltrates were confirmed.
Indeed a 10 fold increase in colonic MPO was shown
in tRag2 vs. ntRag2 reflecting massive neutrophil infiltrationWild type mice
Control diet (n=16) 
Fish oil diet (n=16) 
Rag2-/- mice
tRag2: Control diet (n=10)
tRag2+FO: Fish oil diet (n=1
ntRag2: Control diet (n=10








Figure 1 Study design.(Figure 2D, P < 0.001), as well as significant increases of
pro-inflammatory cytokines, mainly IL-1β, IL-6, KC and
IFNγ (Figure 3, ntRag2 vs. tRag2). Surprisingly, FO-fed an-
imals showed higher levels of colonic MPO (Figure 2D,
tRag2 vs. tRag2 + FO, P = 0.028), IL-1β (Figure 3A, tRag2
vs. tRag2 + FO, P = 0.004), IL-12 (Figure 3B, tRag2 vs.
tRag2 + FO, P= 0.035), KC (Figure 3E, tRag2 vs. tRag2 + FO,
P= 0.035), IL-10 (Figure 3F, tRag2 vs. tRag2 + FO, P= 0.01)
and TNFα (Figure 3G, tRag2 vs. tRag2 + FO, P = 0.006).
Phenotypic and functional analysis of mesenteric lymph
node T cells isolated from colitic mice confirmed the pres-
ence of IFNγ-secreting Th1 cells with about 24% of CD4+
T cells, and to a lesser extent IL-17 secreting Th17 patho-
genic T cells with about 2-3% of CD4+ T cells, whereas
the FoxP3+ regulatory T cells were almost absent <1% of
CD4+ T cells (Figure 4). In addition, supernatants of
anti-CD3 + anti-CD28 or LPS ex vivo stimulation contained
higher level of the same above proinflammatory cytokines
(data not shown). Altogether our data shows that increased
intake of FO neither altered mucosal pathogenic T cells
development nor prevented colitis development.
Colonic eicosanomics
EPA and DHA are described as the most important
anti-inflammatory FA contained in FO. Therefore, as no
or few unexpected differences were observed under FO
consumption, we next wanted to confirm that our diet-
ary intervention does indeed increase the content of
EPA and DHA in healthy animals (ntRag2 vs ntRag2 +
FO) and check AA content as well. After 8-week feeding
animals were sacrificed and AA, DHA and EPA levels
were measured as total free FA in the target tissue i.e.
colon. As shown in Figure 5A, the median AA levels
were at 21.4 ng/mg tissue in the ntRag2 mice while they
were 18.7 ng/mg tissues in the ntRag2 + FO mice. This
difference was not significant. On the other hand, me-
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Figure 2 Measures of colitic outcomes 4 weeks after AT. Shown are body weight measures in grams at sacrifice and in inset shown is
relative body composition with% lean mass in left panel and% fat mass in right panel (A). Endoscopic score is shown (B). Colon weight/length
(W/L) ratio is shown (C). MPO content measured by ELISA is depicted (D). Black bars are median values and each dot represents the value
obtained with an individual mouse. Statistics are shown as * when P <0.05, ** when P <0.01 and *** when P <0.001.
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respectively (P = 0.03). In contrast and as expected,
median levels of DHA shown in Figure 5B were at 8.1
and 18.1 ng/mg tissue in the non transferred mice, i.e.
ntRag2 and ntRag2 + FO (P = 0.002) and 9.4 and 14.7 ng/mg
tissue in the transferred mice, i.e. tRag2 and tRag2 + FO
(P = 0.002). Similarly, EPA levels shown in Figure 5C were
also increased after dietary intervention in both the non-
transferred and the transferred animals median levels
were 0.4 and 2.9 ng/mg tissue in the non transferred
mice, i.e. ntRag2 and ntRag2 + FO (P = 0.002) and 0.3
and 1.6 ng/mg tissue in the transferred mice, i.e. tRag2
and tRag2 + FO (P < 0.001). Overall, we observed an in-
crease in the median levels of free colonic EPA and
DHA by up to 7.2 and 2.2 fold, respectively. Despite
reaching a similar level of AA with both diets in the
non-transferred, a small reduction in AA (0.73 fold) was
observed only in transferred mice which might result
from an increased use induced by the inflammatory
conditions.
The beneficial effects of EPA and DHA are generally
ascribed to the increase in EPA- and DHA-derived metab-
olites instead of AA-derived ones. Thus, we developed a
method to investigated the generation of 22 AA- and 19
EPA/DHA-derived metabolites i.e. eicosanoids in the
colon. The levels of 8 relevant selected AA- and EPA/
DHA- derived metabolites under colitic conditions withthe control and experimental diets are depicted in
Figure 6, while a whole list of 41 metabolites measured
and respective values and statistics are given in Additional
files 1 and 2. In accordance with the changes in the pre-
cursors, most of the EPA- and DHA- derived metabolites
described as anti-inflammatory molecules increased fol-
lowing FO diet. We confirmed the release of the precur-
sors as well as the formation of the COX (prostaglandin
(PG)E3 and thromboxane (Tx)B3, Figure 6A-B), LOX
(leukotriene (LT) B5 and 5-hydroxyeicosapentaenoic
acid (5-HEPE), Figure 6C-D) and CYP450 (17,18-
epoxyeicosatetraenoic acid (17,18-EEP), Figure 6E) de-
rived metabolites of EPA and DHA in the colon following
our dietary intervention. With respect to AA-derived me-
tabolites, despite a significant decrease in free AA in the
colon, only a few metabolites were reduced, namely PGJ2
(Figure 6F), 5,6-epoxyeicosatrienoic acid (5,6-EET), 8,9-
EET (Figure 6G) and 14,15-EET. Thus, the decrease in
free AA did not translate into a reduction of important
proinflammatory mediators such as PGE2 (Figure 6H),
TXB2 and LTB4 (Additional files 1 and 2). Furthermore,
it should be noted that the absolute amounts of the
series 2 and the series 3 metabolites, arising from AA
and EPA, respectively, differed by almost 1 order of magni-
tude in favour of series-2 metabolites indicating that there
was not a substantial redirection of eicosanoid expression
into series-3 metabolites in this experimental model.
Figure 3 Cytokine measurements in colon tissue. IL-1β; IL-12p70; IFNγ; IL-6; KC; IL-10 and TNFα are shown (from A-G respectively). Black bars
are median values and each dot represents the value obtained with an individual mouse. Statistics are shown as * when P <0.05, ** when P <0.01
and *** when P <0.001.
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An earlier transcriptomic study with FO intervention had
shown inhibitory effects on nuclear factor-κB (NF-κB) reg-
ulated genes in human PBMCs [29]. Thus we wanted to
determine whether colitic processes are modulated by FOdiet in the target organ i.e. colon. RNA from colonic tissue
was isolated 28 days after AT and subjected to genome-
wide screening. Microarray analysis identified 6353 probes
that were differentially expressed between healthy and
colitic mice (Figure 7A). Among them, 215 and 50 genes
Figure 4 Phenotypic analysis of T-helper cells in mesenteric lymph nodes at 4 weeks after AT. Ex-vivo T cell stimulation, fixation and
staining were performed then analyzed by flow-cytometry. Representative flow-cytometry dot plot pictures and gating strategy to quantify% of
Th1, Th17 and regulatory T cells (A). Note the clear differences in each subset frequency between a healthy mice and colitic mice irrespectively of
the diet used.% of Th1, Th17 cells and regulatory T cells are shown in colitic mice (tRag2 and tRag2 + FO) (B). Black bars are median values and

























Figure 5 Colonic free FA levels of AA, DHA and EPA. AA, DHA and EPA levels are shown for each experimental group (from A-C respectively).
Black bars are median value and each dot represents the value obtained with an individual mouse. Statistics are shown as * when P <0.05,
** when P <0.01 and *** when P <0.001.
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Figure 6 Levels of EPA and AA-derived metabolites in colon. Free fatty acid levels of EPA-derived metabolites prostaglandin E3 (PGE3);
thromboxane B3 (TxB3); leukotriene B5 (LTB5); 5-hydroxyeicosapentaenoic acid (5-HEPE); 17,18-epoxyeicosatetraenoic acid (17,18-EEP); and the
AA-derived metabolites prostaglandin J2 (PGJ2); 8,9-epoxyeicosatrienoic acid (8,9-EET); prostaglandin E2 (PGE2) (from A-H respectively) are
shown. Black bars are median values and each dot represents the value obtained with an individual mouse where dark circles are tRag2 and
open circles are tRag2 + FO. Statistics are shown as * when P <0.05, ** when P <0.01 and *** when P <0.001. Of note whole set of metabolites
measured and corresponding values are given in Additional files 1 and 2.
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Figure 7 Transcriptomic analysis of colon preparation in healthy and colitic mice. Shown is Venn diagram made with significantly
regulated colonic genes (P < 0.001) showing the relative impact of diet (treatment) vs. colitis (induction) and interaction between diet and colitis
(A). Two-dimensional visualization of unsupervised PCA analysis constructed with the whole set of gene significantly differentially expressed in
the colon upon colitis induction (B). Each dot represents the value obtained with an individual mouse (n = 6-9 mice per group). Of note top 40
colonic genes up- and down regulated in colitis mice and corresponding value are given in Additional files 3 and 4.
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Mucosal inflammatory processes are evidenced by top
40 up- and down-regulated genes found in colon mRNA
preparation of colitis mice (Additional files 3 and 4).
We observed important increased expression of a set
of genes belonging to proinflammatory cytokine (IL-1β,
4 fold), chemokine family (CXCL9, CCL5, CCL8, CXCL10
and CCL4 up to 22.4 fold) or acute phase proteins (SAA1,
7 fold). It explained massive leukocyte infiltration sup-
ported by high expression of neutrophil related genes
(formyl peptide receptor (FPR)-2 or CD16a up to 10.3
fold) or T cell specific gene (CD3γ and CD52 up to 4.8
fold). Epithelial cell activation is also evidenced by raised
expression of major histocompatibility complex (MHC)
class I or II or costimulatory molecules (i.e. H2 molecules,
CD74 known as MHC-II invariant chain and CD274
known as PD-L1 or B7-H1) up to 6.4 fold as well as
intestinal anti-microbial peptide expression (S100A8,
lysozyme 2 and Reg3α up to 6.4 fold). Interestingly these
expression patterns have also been reported in human or
animal studies using different models of IBD namely DSS
or TNBS mediated intestinal inflammation [2,30]. In par-
allel, as a reflection of the mucosal functional impairment
associated with colitis, we also observed about a 2–3 fold
reduced expression of a set of genes reported to play
major a role on water (aqp1-aquaporin 1 [31]), electrolytes
(slc24a3-solute carrier family 24 member A3 being a
Na+/K+/Ca2
+ exchanger [32] or FXYD4 or FXYD6-FXYD
domain containing ion transport regulator 4 or 6 [33]) orvitamin (slc5a6 – solute carrier family 5 member A6 being
a Na+-dependent multivitamin transporter [34]) absorp-
tion. In addition, in colitic mice, despite increased FO
intake, some important genes involved in endothelial
smooth muscle function (e.g. actg2–gamma 2 enteric
smooth muscle actin [35], synm-synemin also known as
desmuslin [36], or myh11–smooth muscle myosin heavy
chain 11 [37]) were down-regulated by up to 2.3 fold.
Interestingly mptx gene -mucosal pentraxin- a previoulsly
reported rodent-specific biomarker of gut health [38] was
also decreased by >2 fold. Overall, this might reflect
general alteration of colonic tissue histology and function.
Importantly, only 38 probes were differentially regu-
lated by dietary intervention as shown in Venn diagram
(Figure 7A). As mentioned in the methods, the analyses
were performed at an alpha of 0.001 which yielded a
false positive rate of ~26. Further, while more than 2000
probes were changed by more than 25% with colitis, no
probes were altered by more than 25% specifically by
the diet. Thus, we believe that the impact of FO was
negligible under these conditions in the inflamed co-
lonic tissue. In agreement with this observation, global
unsupervised analysis did not reveal any effect of FO
diet on inflammation as visualized by PCA analysis on
the total set of 25697 probes analyzed (Figure 7B).
Conclusions
Our dietary intervention study was aimed at increasing
cellular EPA and DHA content while maintaining
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tures of colitis development in a mouse model of IBD.
Despite increased dietary intake of n-3 PUFAs via FO
and efficient colonic incorporation of EPA and DHA, we
did not observe protection against colitis onset in our
mouse model 4 weeks after disease induction. The dif-
ferences between our studies and others might be
explained by multiple variables like diet, species, and the
nature and or severity of the IBD model used. Herein,
we carefully established a diet maintaining total n-6
PUFA content in both control and experimental diet, in
order to strictly examine the impact of increased intakes
of n-6 PUFA i.e. EPA and DHA rather than the relative
decrease of AA observed in many studies which can be a
confounding factor. However, our diet did not convey anti-
inflammatory activity or at least sufficient enough to pre-
vent colitis. Indeed despite FO-based dietary intervention,
in colitic mice mucosal proinflammatory chemokines and
cytokines mRNA and protein levels were maintained or
even exacerbated, pathogenic Th1/Th17 cells present and
neutrophil infiltrates increased. As we fed animal before
colitis induction and stopped our experiments 4 weeks,
for internal ethical reasons, we cannot firmly anticipate
subsequent positive impact or therapeutic properties of
FO-based diet.
A recent study by Fenton and colleagues, using a different
approach with smad-3−/− mice infected with Helicobacter
hepaticus as a colitis model [19], showed that inflammation
severity and dysplasia was positively correlated with the
amount of FO present in the diet, the reduction of CD8+ T
cell frequency and the increase in regulatory T cell fre-
quency at week 4 post-infection. AT colitis model con-
sists in syngeneic transfer of naïve CD4+ T cells into
lymphopenic mice, thus CD8+ T cells and regulatory T
cells are normally absent or very limited in numbers
(due to poor contamination of inoculums). Transferred
T cells dramatically expand and particularly in colon in re-
sponse to microbiota non-self antigens due to empty space
and lack of regulatory mechanisms provided by regulatory
T cells, colitis develops without any need of infection
[26,39]. These major differences might explain why in
our settings FO-diet did not dramatically exacerbate the
colitis. The impact of an infection subsequently to col-
itis induction by AT might be interesting to study as
well as the effects of fish oil in such settings.
Herein, we studied for the first time the combined ef-
fect of dietary n3-PUFA and or inflammation on colonic
eicosanoid metabolism in vivo. Efficient incorporation of
EPA and DHA in the colonic tissue as well as generation
of EPA- and DHA-derived anti-inflammatory metabo-
lites were confirmed through eicosanomic analysis. A
“favorable” lipid signature was found but unfortunately
not enough to identify a cause to prevent colitis as one
would have expected. Very similar conclusions wereobtained in mouse models of arthritis by Lyme infection
or sepsis [40,41]. Brown and colleagues managed to sig-
nificantly shift eicosanoid profile in arthritic ankle joints
by substitution of soybean oil with FO in the diet but
did not change host inflammatory response or devel-
opment of arthritis [40]. The same is true for sepsis as
Witkamp and collegues showed that FO intake generally
increased series-3 eicosanoids but failed to improve septic
signs and detect resolvins [41]. Of note, mice who re-
ceived higher dose of FO displayed relatively more se-
vere signs of sepsis.
We observed that absolute amounts of the series-2
eicosanoids arising from AA and the series-3 eicosanoids
arising from EPA, differed by almost 1 order of magnitude
(Additional files 1 and 2). Therefore, we assume that
despite high dietary intake, it might be difficult or even
impossible to counterbalance proinflammatory effects
of series-2 eicosanoids competing for the same recep-
tors as anti-inflammatory series-3 eicosanoids in physio-
logical situation. Therefore in some settings where this
balance can be efficiently impaired like fat-1 transgenic
animals, better inflammatory outcomes are obtained
[42-44]. In contrast to unmanipulated mammals where
n-3 PUFA almost exclusively come from diet (as herein),
fat-1 transgenic mice expressing C. elegans fat-1 gene
i.e. an n-3 fatty acid desaturase and can convert dietary
n-6 PUFA into n-3 PUFA in all tissues. Those mice were
protected against TNBS- or DSS-induced colitis. Two
protective mechanisms were described. First it leads
to a significant increase in anti-inflammatory lipid me-
tabolites derived from n3-PUFA namely protectin D1,
resolvin E1 and D3 whereas pro-inflammatory lipid
metabolites derived from n6-PUFA like LTB4 and PGE2
were kept constant [42,43]. More recently Chapkins and
colleagues showed that colonic mucosal microenviron-
ment was altering regulatory T cells/Th17 cells ratio in
fat-1 mice [44]. These data highlight the importance of
the nature of the anti-inflammatory lipid metabolites
but also their relative amounts in target tissue. Eicosa-
noids not only play a role on inflammation, they could
also support mucosal pathogenic Th17 cells generation
[45]. In our experimental condition, we neither observe
alteration in helper T cell numbers and subsets nor
detect resolvins in line with the lack of efficacy of our
dietary FO treatment. Overall n3-derived lipid metabolites
were 10–100 fold lower than their n-6 counterparts. This
important bias in n-3:n-6 eicosanoid stoichiometry might
explain why colitis amelioration was not achieved despite
the substantial EPA and DHA precursor dose provided
within the diet. In that respect, new tricks that could be
translated to human clinics, to improve n3-derived lipid
metabolites generation or n3:n6 ratio in vivo deserve
further investigations. This could be achieved by the
concomitant use of dietary FO with phospholipase A2
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proinflammatory eicosanoids [46]) and or COX-2 inhib-
itors (to promote resolvins generation [47]).
To fully complete our work and gain larger insight
into the effect of dietary EPA and DHA on colonic inflam-
mation, microarray analysis was performed with tissue
from healthy or colitic mice under control or experimental
diet. Multivariate data modeling validated our previous
findings showing limited effects on colonic gene expres-
sion induced by FO consumption. Indeed, expression
levels of proinflammatory markers, e.g. chemokines and
acute phase proteins, and epithelial cell stressors were
unaffected. As this observation was made out of global
tissue rather than cell specific examination, we cannot
rule out that dietary EPA and DHA control gene expres-
sion profiles in a tissue and cell specific way. For in-
stance, significant impact of similar amount of dietary
EPA and DHA on liver or PBMC gene expression profile
was previously documented [29,48]. Herein, we demon-
strate that colon gene expression profile is less influenced
by dietary LC n-3 PUFA. Further examinations of colon
epithelial cells or intra epithelial lymphocytes deserve fur-
ther investigations.
We reported new important intestinal events associated
with colitis which might explain morphological and func-
tional alteration of the colon. For instance, we observed a
significant reduction in slc5a6 gene expression coding for
Na+-dependent multivitamin transporter. SLC5A6 is a
crucial transporter of biotin, a water-soluble vitamin
required for normal cellular function, growth and de-
velopment [34]. Intestinal-specific deletion of slc5a6 was
recently reported in mice [34]. Two-thirds of the intestinal
slc5a6−/− mice died prematurely due to acute peritonitis.
The remaining mice displayed important reduction of
blood biotin level associated to growth retardation and
specific intestinal inflammation and histological alter-
ations. In that respect, vitamin status in preclinical model
of IBD or patients, which often display multiple vitamin
deficiencies [49] deserves better attention as well as spe-
cific means to restore normal levels.
How can this data be further translated to human?
IBD is a disease with remission-relapse periods where
induction and maintenance therapies should be consid-
ered. Our model like others does not address properly
this dynamic feature of IBD as a relapsing disease with
inflammatory and healing episodes. However, clinical trial
results assessing the role of FO in both stages exist and
also ruled out potential benefits of EPA and DHA in
induction or maintenance therapies [22-24,50]. Concerning
the dose provided to the animal, we estimate that about
10 mg EPA +DHA per animal per day were consumed. It
represents a human equivalent dose (HED) [51] of about
41 mg per kg of body weight per day i.e. about at least 3
supplement pills (of the highest marketed concentration)or ~250 grams daily consumption of wild salmon in
healthy adults of average body weight of 70 kg. Such a
high dose is close to the highest daily intake recorded in
epidemiological studies where EPA +DHA dietary intake
was associated with IBD disease reduction risk [52]. How-
ever, no efficacy was shown herein as well as in clinical tri-
als. Thus, no firm recommendations about the usefulness
of n-3 LC-PUFAs can be made for UC or CD patients.
We also believe that important genetic or environmental
factors not addressed in epidemiological studies might at
least partially contribute to the preventive action attrib-
uted to n3-PUFA against IBD.
In summary, our results show that increase intake of
dietary n-3 PUFA in mice does not reduce colitis devel-
opment in AT colitis model. Transcriptomic analysis
reveals a limited impact of these dietary lipids on IBD.
In contrast, eicosanomic analysis reveal significant in-
crease of some anti-inflammatory colonic eicosanoids
when mice where fed with FO. However, even though
some of these mediators might play a positive role in
colitis prevention, their presence in limited amount
relative to the proinflammatory mediators derived from
AA was not sufficient to alleviate colitis.Materials and methods
Animals, housing and diets
Wild-type (WT) or Rag2−/− C57BL/6 breeder mice were
purchased from CDTA Orleans (France). Breeding was
maintained in specific pathogen-free conditions at Nestlé
research center animal care facility then transferred to
conventional housing conditions and kept in ventilated
cages for our experiments. Animals had free access to
diet and tap water. Control and experimental diets com-
position are given in Table 1 and based on a standard
AIN-93G rodent diet then FA composition of both diets
was checked by classical methods as described previously
[53] and given in Table 2. Based on an average mouse
body weight of 20 g and 4 g of daily food intake, our mice
consumed about 10 mg per day of EPA +DHA. This dose
is equivalent to ~41 mg/kg/day in humans according to
the human equivalent dose formula (HED) calculated as
HED(EPA+DHA) = animal dose in mg/kg × (animal weight
in kg/human weight in kg)0.33 [51]. Powders were
transformed into pellets, dried at low temperature and
stored in small sachets under vacuum at −20°C. The di-
ets were changed twice a week in each animal cage.
These precautions were taken to avoid oxidative deg-
radation of lipids. Female mice between 8–12 week old
were used. WT or Rag2−/− animals were fed either the
control or experimental diet 4 weeks prior to colitis
induction and under the same diet for 4 additional weeks
as depicted in study design (Figure 1). All experiments
were conducted according to the Nestlé animal welfare
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offices (authorisation number VD-2076.1).
Colitis induction
At the time of colitis induction WT mice (n = 10) from
each group (control or experimental diet) were eutha-
nized, 5x105 naïve CD4+CD25-CD45RBHigh T-cells were
isolated and i.p. transferred into Rag2−/− mice to induce
colitis as described previously [2,26,27,39]. The remaining
WT mice and the Rag2−/− mice, both transferred (t) and
non-transferred (nt), were further fed the control and
experimental diets as depicted in Figure 1 for another
4 weeks a timing previously established for first signs
of IBD apparition [27]. Along the 4 week period post-
transfer, mice were observed for clinical signs of well-
being and illness. At sacrifice (day 28–29 post transfer),
colons were removed from ileo-cecal junction to rectum,
cleaned with cold PBS then weight and length were mea-
sured before being snap-frozen in liquid nitrogen.
Colonoscopy and body composition
The COLOVIEW mini-endoscopic system was used as
previously described [54]. Distal colon was examined along
the first 3–4 cm. Scoring system [0–30] consists in evalu-
ation of ulceration numbers (0–6), vasculature features
(0–3), mucosal granularity (0–3), erythema (0–3), pin-
points (0–3), fibrin deposition (0–3), length involved (0–6)
and overall vulnerability (0–3) of the colon. Fat and lean
body mass were measured with NMR (EchoMRI 2004)
the day before the sacrifice and expressed as% of animal
body weight.
Helper T cell (Th) and regulatory T cell characterization
Mesenteric lymph node cell suspensions were made to
assess in AT mice Th1 and Th17 cells ex vivo as described
previously [27]. Th1 cells were CD4+IFNγ+ whereas Th17
cells were CD4+IL-17+. Additionally, anti-FoxP3 intranuclear
staining was made in order to track the generation of so-
called CD4+FoxP3+ regulatory T cells. All antibodies were
purchased from eBiosciences.
Cytokines and myeloperoxidase (MPO) measurements
Ultrasensitive multiplex cytokine profiling kit (Meso
Scale Discovery) was used to assess mouse IL-1β, IL-6,
keratinocyte-derived chemokine (KC) (mouse IL-8), IL-10,
IL-12p70, IFNγ and TNF-α in colonic protein extracts
according to manufacturer’s instructions. Proteins from
colon samples were prepared in RIPA buffer (Sigma) and
protein measured with RC-DC Protein assay kit (BIORAD).
MPO content of the colon protein extracts was determined
with an ELISA kit (Hycult Biotech) following the manu-
facturer’s instructions. Cytokines or MPO levels were
normalized to total tissue protein contents.Microarray analysis
As previously described [55], colon samples were homoge-
nized in lysis buffer using a FastPrep instrument, in lysing
tubes containing ceramic beads (MP Biomedicals, Irvine,
CA, USA). Total RNA was extracted and purified with the
RNAdvance tissue kit (Agencourt, Beverly, MA, USA).
The quality of RNA samples was checked by using the
Agilent 2100 Bioanalyzer (RNA integrity numbers ≥ 8 for
high quality; Agilent Technologies, Santa Clara, CA, USA).
All cRNA targets were synthesized, labeled, and purified
according to the Illumina TotalPrep RNA amplification
protocol (Applied Biosystems, Austin, TX, USA). Then,
15 μl of each hybridization mix was dispensed on the
microarrays (16 h, 58°C), the microarrays were washed
to remove non hybridized material and stained with
Streptavidin-Cy3. All samples were analyzed with the
microarrays MouseRef-8 v2 Expression BeadChips (Illumina,
San Diego, CA, USA).Eicosanomics analysis
AA, EPA, DHA and their respective derived metabolites
were quantified by HPLC-MS/MS as described earlier [53].
Calibration curves were generated from amounts of 10 pg
to 1 ng of undeuterated standards (Cayman Chemical,
USA) and a fixed quantity of deuterated internal standards
(1 ng) for each analyte. Quantitation of analytes was done
with the Analyst (1.5.1) software.Statistical analysis
Except microarray data, all the data presented herein were
analyzed with the 2-sided Wilcoxon rank sum test with
the R software, version 2.12.0. Differences were considered
statistically significant for P value <0.05. Since this is
non-parametric, median values were used. Differential
gene expression obtained by between the groups with
colitis induction and diet as factors was analyzed with a 2-
way ANOVA followed by a-posteriori contrasts. Micro-
array gene expression data are presented as fold change
for top-40 genes, based on the P value cutoff <0.001 and
analyzed with the Ingenuity Pathways Analysis software
(IPA; Ingenuity Systems).Additional files
Additional file 1: List of AA-derived metabolites quantified in colon
and values. Colon preparations of control and colitis animals under
control- or FO-diet were analyzed. Medians are expressed in pg/mg of
tissue. Significant differences between group comparisons are
highlighted in grey.
Additional file 2: List of DHA- and EPA-derived metabolites
quantified in colon and values. Colon preparations of control and
colitis animals under control- or FO-diet were analyzed. Medians are
expressed in pg/mg of tissue. Significant differences between group
comparisons are highlighted in grey.
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expressed genes in colitis mice compared to control mice fed with
control diet are shown. All with P < 0.001, with n = 8 and 9 mice for
ntRag2 and tRag2 respectively. Illumina ID probe number is given.
Additional file 4: Top 40 down-regulated colonic genes.
Differentially expressed genes in colitis mice compared to control mice
fed with control diet are shown. All with P < 0.001, with n = 8 and 9 mice
for ntRag2 and tRag2 respectively. Illumina ID probe number is given.
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